argenx SE

argenx SE

World Rank (Jul-30-2023)
621
Market Cap (Jul-30-2023)
30.54 Billion USD
World Rank (Dec-25-2022)
799
Market Cap (Dec-25-2022)
20.88 Billion USD
World Rank (Jan-07-2022)
1,257
Market Cap (Jan-07-2022)
16.13 Billion USD
World Rank (Jan-01-2021)
1,255
Market Cap (Jan-01-2021)
14.02 Billion USD
Company Rank in Country in 2022
Rank in Netherlands in 2022 is 21
CEO
Tim Hauwermeiren
Employee Count
843
Employee Count as of Date
As on 2022
Headquarters Country
Netherlands
Annual Revenue in USD
410 Million USD
Annual Operating Income in USD
-719 Million USD
Annual Net Income in USD
-709 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
3,134 Million USD
Total Liabilities in USD
320 Million USD
Total Equity in USD
2,813 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector LC
Healthcare
Pharmaceutical
Biopharmaceutical
Biotechnology
Technology
Company Website
ARGENX SE
Yahoo
Yahoo @ Nasdaq
Company Profile

Biopharmaceutical company with headquarters in Netherlands.

Annual Results Summary LC

ARGENX SE - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-2022410-719 (Loss)-709 (Loss)
Dec-2021497-348 (Loss)-408 (Loss)
Dec-202044-516 (Loss)-650 (Loss)
Balance Sheet Summary LC

Total Assets as on Dec-2022 was 3,134 Million USD.

Total Liabilities as on Dec-2022 was 320 Million USD.

Total Equity as on Dec-2022 was 2,813 Million USD.

Founded Year
2008
IPO Year
2017
Stock Exchange LC
Nasdaq
Frankfurt